The 2nd Priority Review Voucher Summit 2017 is dedicated to the regulatory landscape, valuation approaches, benefits and challenges of developing a drug that would be eligible for a Priority Review Voucher.
Topics
- The changing regulatory landscape and the future of the program
- The various priority review voucher programs and their respective eligibility requirements
- The challenges of clinical study design , operational logistics and patient engagement for developing rare disease therapeutics
- The various valuation models to utilize before buying or selling a priority review voucher
- Regulatory requirements - composing and submitting compliant documentation
Who should Attend
Attendees from pharmaceutical companies, social enterprises, patient groups, government agencies and the investment community.
